Autologous MSC-NTF cells in progressive multiple sclerosis
Progressive MS - both primary and secondary progressive - is characterized by worsening neurologic function and increasing disability over time. There are no available therapies that halt the progression of established disability or result in functional improvement.
Second indication
Progressive multiple sclerosis
Progressive MS - both primary and secondary progressive - is characterized by worsening neurologic function and increasing disability over time. There are no available therapies that halt the progression of established disability or result in functional improvement.
Evidence from preclinical models suggests MSC-NTF cells have potential for immunomodulation, remyelination and neuroprotection. BrainStorm has completed a Phase 2 open-label trial using repeat administration in progressive MS.
- 85%
of people with MS have the relapsing-remitting form
- ~10%
are diagnosed with primary progressive MS
- ~50%
of RRMS patients eventually transition to secondary progressive MS
- 20–70
age range at which onset can occur
Study NCT03799718
Phase 2 open-label trial
Phase 2 open-label trial using repeat administration in participants with primary or secondary progressive multiple sclerosis.
- Phase
- Phase 2
- Design
- Open-label, repeat administration
- Location
- United States
- Status
- Completed
- Participants
- 20 enrolled · 18 treated · 16 completed
Keep reading
All programsBrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.